Humanigen WKN: A2QEQW ISIN: US4448632038 Kürzel: HGEN Forum: Aktien Thema: Hauptdiskussion
Kommentare 948
AirRailey,
25.07.2023 13:22 Uhr
1
All In
Trierer82,
25.07.2023 12:42 Uhr
0
Nur noch OTC Markt
Trierer82,
25.07.2023 12:42 Uhr
0
Delisting kommt
AirRailey,
23.06.2023 11:00 Uhr
0
Kommt hier noch was?
jbaumgrtnr,
16.06.2023 14:10 Uhr
0
Was ist los?
oxanabanana,
09.06.2023 18:08 Uhr
0
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response
Building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durable
CMML is a rare, aggressive cancer; approximately 20% of patients survive three years from diagnosis
No new CMML medications with novel mechanisms of action have been approved in over 30 years and hypomethylating agents, such as azacitidine alone, are currently considered "standard of care"
oxanabanana,
09.06.2023 18:08 Uhr
0
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
oxanabanana,
19.04.2023 12:07 Uhr
0
On April 18, 2023, Humanigen, Inc. (the “Company”) was notified that it had been granted an extension until August 21, 2023 to demonstrate compliance with all applicable requirements for listing of the Company’s common stock on Nasdaq by the Nasdaq Hearings Panel (the “Panel”), subject to the Company’s compliance with the Panel’s requirements for periodic updates relating to the status of the Company’s progress against achievement of the compliance plan presented at the April 6, 2023 hearing with the Panel.
There can be no assurance that the Company will be successful in its execution of its compliance plan or otherwise regain compliance with the applicable Nasdaq listing requirements within the extended compliance period.
Thombo,
17.04.2023 14:05 Uhr
0
Wenn eine 2 vor dem Komma steht, denke ich an Dich
Thombo,
17.04.2023 10:12 Uhr
0
Wieso nur hinkt dieses ***** TR immer hinterher 🙈
oxanabanana,
14.04.2023 21:16 Uhr
0
Bei meinem EK lohnt es sich nicht zu verkaufen. Entweder delisting oder Rakete
oxanabanana,
14.04.2023 21:16 Uhr
0
Natürlich, bin immernoch dabei.
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | ATOS Hauptdiskussion | +10,00 % | |
2 | BTC/USD Hauptdiskussion | +0,06 % | |
3 | Media and Games Invest | -4,04 % | |
4 | Brainchip Klassengruppe | +24,59 % | |
5 | MicroStrategy | -8,78 % | |
6 | CARL ZEISS MEDITEC Hauptdiskussion | +5,49 % | |
7 | ETH/USD | +4,80 % | |
8 | Vulcan Energy Resources Hauptdiskussion | -5,11 % | |
9 | NVIDIA Hauptdiskussion | +3,69 % | |
10 | DELL TECHNOLOGIES Hauptdiskussion | +2,47 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | ATOS Hauptdiskussion | +10,00 % | |
2 | Media and Games Invest | -4,04 % | |
3 | Brainchip Klassengruppe | +24,59 % | |
4 | MicroStrategy | -8,78 % | |
5 | CARL ZEISS MEDITEC Hauptdiskussion | +5,49 % | |
6 | Vulcan Energy Resources Hauptdiskussion | -5,11 % | |
7 | NVIDIA Hauptdiskussion | +3,69 % | |
8 | DELL TECHNOLOGIES Hauptdiskussion | +2,47 % | |
9 | HAYDALE GRAPH.INDUS.LS-02 Hauptdiskussion | +11,11 % | |
10 | TESLA MOTORS Hauptdiskussion | +2,27 % | Alle Diskussionen |